Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Identifieur interne : 001D06 ( Ncbi/Merge ); précédent : 001D05; suivant : 001D07Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Auteurs : O. Rascol [France] ; N. Fabre ; O. Blin ; J. Poulik ; U. Sabatini ; J M Senard ; M. Ané ; J L Montastruc ; A. RascolSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Aged, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Female, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Motor Skills (drug effects), Naltrexone (adverse effects), Naltrexone (therapeutic use), Neurologic Examination (drug effects), Parkinson Disease (drug therapy).
- MESH :
- chemical , adverse effects : Bromocriptine, Levodopa, Naltrexone.
- chemical , therapeutic use : Bromocriptine, Levodopa, Naltrexone.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.
DOI: 10.1002/mds.870090410
PubMed: 7969211
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001673
- to stream PubMed, to step Curation: 001632
- to stream PubMed, to step Checkpoint: 001632
Links to Exploration step
pubmed:7969211Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name></author><author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J" last="Poulik">J. Poulik</name></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M" last="Ané">M. Ané</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7969211</idno><idno type="pmid">7969211</idno><idno type="doi">10.1002/mds.870090410</idno><idno type="wicri:Area/PubMed/Corpus">001673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001673</idno><idno type="wicri:Area/PubMed/Curation">001632</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001632</idno><idno type="wicri:Area/PubMed/Checkpoint">001632</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001632</idno><idno type="wicri:Area/Ncbi/Merge">001D06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name></author><author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J" last="Poulik">J. Poulik</name></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M" last="Ané">M. Ané</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Naltrexone (adverse effects)</term><term>Naltrexone (therapeutic use)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Naltrexone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Naltrexone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7969211</PMID><DateCreated><Year>1994</Year><Month>12</Month><Day>14</Day></DateCreated><DateCompleted><Year>1994</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>437-40</MedlinePgn></Pagination><Abstract><AbstractText>One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabre</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Poulik</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Ané</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001971" MajorTopicYN="N">Bromocriptine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7969211</ArticleId><ArticleId IdType="doi">10.1002/mds.870090410</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M" last="Ané">M. Ané</name><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J" last="Poulik">J. Poulik</name><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001D06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:7969211
|texte= Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:7969211" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |